Hypomagnesaemia (low serum magnesium: PPIs, diuretics, alcohol, diarrhoea)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Hypomagnesaemia found (< 0.7 mmol/L), without severity signs
Laboratory tests
- Serum electrolytes (potassium)
- Serum calcium
- Serum albumin
- Serum creatinine with eGFR
- Fasting plasma glucose (if diabetes not known)if needednon-French guidelineDiabetes is among the causes to look for in hypomagnesaemia [2].
- Bicarbonate (if associated hypokalaemia)if neededHypokalaemia with hypomagnesaemia: a metabolic alkalosis without digestive cause suggests diuretic intake or Gitelman syndrome [3].
If no obvious cause: blood and urine the same day
- Serum magnesium, serum creatinine, and on a urine sample taken at the same time: urinary magnesium and urinary creatinine (to calculate the fractional excretion of magnesium)if neededNo obvious cause (PPI, diuretic, alcohol, diarrhoea, diabetes): the fractional excretion of magnesium distinguishes renal loss (> 4%) from an extrarenal cause (2% or less) [2,3]. The urine collection must be simultaneous with the blood sample [3].
Sources (12)
- Čabarkapa V, Đerić M, Todorović M, et al. Hypomagnesemia in adults of northern Serbia: prevalence, nutritional risk factors, and associated comorbidities. Magnes Res. 2019;32(1):25-36.
- Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis. 2014;7:219-30.
- Centres de référence des maladies rénales rares (MARHEA, filière ORKiD). Protocole national de diagnostic et de soins (PNDS) : Syndrome de Gitelman. Novembre 2022, actualisation février 2025 (publié sur has-sante.fr ; non validé par la HAS).
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit MOPRAL 20 mg (oméprazole), rubriques 4.4 et 4.8, consulté le 11 octobre 2026.
- Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237-41.
- US Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). 2 mars 2011.
- Medicines and Healthcare products Regulatory Agency (MHRA). Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update, avril 2012, vol. 5, n° 9 : A1.
- Zorginstituut Nederland. Farmacotherapeutisch Kompas : omeprazol, rubrique « Waarschuwingen en voorzorgen », consulté le 30 octobre 2026.
- Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-715.
- Rosanoff A, West C, Elin RJ, et al. Recommendation on an updated standardization of serum magnesium reference ranges. Eur J Nutr. 2022;61(7):3697-3706.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit HYDROCHLOROTHIAZIDE ARROW 12,5 mg, comprimé sécable, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit CONFEROPORT 1 mg (tacrolimus), gélule à libération prolongée, rubrique 4.8.